TORNTPHARM Stock Overview
Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, and marketing of generic pharmaceutical formulations in India, the United States, Brazil, Germany, and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 5/6 |
| Past Performance | 6/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
Torrent Pharmaceuticals Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹2,694.30 |
| 52 Week High | ₹2,744.00 |
| 52 Week Low | ₹1,598.45 |
| Beta | 0.29 |
| 1 Month Change | 4.82% |
| 3 Month Change | 8.93% |
| 1 Year Change | 65.37% |
| 3 Year Change | 115.51% |
| 5 Year Change | 204.63% |
| Change since IPO | 22,352.50% |
Recent News & Updates
Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) P/E Is On The Mark
Apr 16
Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Have A Healthy Balance Sheet?
Mar 03Recent updates
Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) P/E Is On The Mark
Apr 16Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Have A Healthy Balance Sheet?
Mar 03Torrent Pharmaceuticals (NSE:TORNTPHARM) Is Increasing Its Dividend To ₹22.00
Feb 05Investors Interested In Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) Earnings
Jan 07Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Rather Sparingly
Nov 14Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Jun 01Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Mar 01Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Jul 25Torrent Pharmaceuticals' (NSE:TORNTPHARM) Soft Earnings Don't Show The Whole Picture
Jun 02Estimating The Fair Value Of Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)
May 25A Look At The Intrinsic Value Of Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)
Feb 18Torrent Pharmaceuticals (NSE:TORNTPHARM) Is Increasing Its Dividend To ₹25.00
Jan 27Here's Why Torrent Pharmaceuticals (NSE:TORNTPHARM) Can Manage Its Debt Responsibly
Jan 04Here's Why I Think Torrent Pharmaceuticals (NSE:TORNTPHARM) Is An Interesting Stock
Dec 14A Look At The Fair Value Of Torrent Pharmaceuticals Limited (NSE:TORNTPHARM)
Nov 07Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Sep 30Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Deserve A Spot On Your Watchlist?
Sep 01Torrent Pharmaceuticals (NSE:TORNTPHARM) Seems To Use Debt Quite Sensibly
Jul 02I Ran A Stock Scan For Earnings Growth And Torrent Pharmaceuticals (NSE:TORNTPHARM) Passed With Ease
Jun 01Torrent Pharmaceuticals Limited (NSE:TORNTPHARM) Shares Could Be 30% Above Their Intrinsic Value Estimate
May 14Does Torrent Pharmaceuticals (NSE:TORNTPHARM) Have A Healthy Balance Sheet?
Mar 23The Torrent Pharmaceuticals (NSE:TORNTPHARM) Share Price Has Gained 84% And Shareholders Are Hoping For More
Mar 02Is It Smart To Buy Torrent Pharmaceuticals Limited (NSE:TORNTPHARM) Before It Goes Ex-Dividend?
Feb 10Do Torrent Pharmaceuticals's (NSE:TORNTPHARM) Earnings Warrant Your Attention?
Jan 19Should You Be Impressed By Torrent Pharmaceuticals Limited's (NSE:TORNTPHARM) ROE?
Dec 29Is Torrent Pharmaceuticals (NSE:TORNTPHARM) Using Too Much Debt?
Dec 08
Investors Who Bought Torrent Pharmaceuticals (NSE:TORNTPHARM) Shares Three Years Ago Are Now Up 118%
Nov 16The Torrent Pharmaceuticals Limited (NSE:TORNTPHARM) Second-Quarter Results Are Out And Analysts Have Published New Forecasts
Oct 28Here's Why We Think Torrent Pharmaceuticals (NSE:TORNTPHARM) Is Well Worth Watching
Oct 07Torrent Pharmaceuticals Limited (NSE:TORNTPHARM) Delivered A Better ROE Than Its Industry
Sep 16Shareholder Returns
| TORNTPHARM | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 5.8% | 1.4% | 2.8% |
| 1Y | 65.4% | 57.2% | 46.6% |
Return vs Industry: TORNTPHARM exceeded the Indian Pharmaceuticals industry which returned 55.9% over the past year.
Return vs Market: TORNTPHARM exceeded the Indian Market which returned 46.4% over the past year.
Price Volatility
| TORNTPHARM volatility | |
|---|---|
| TORNTPHARM Average Weekly Movement | 3.3% |
| Pharmaceuticals Industry Average Movement | 5.9% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in IN Market | 10.1% |
| 10% least volatile stocks in IN Market | 4.2% |
Stable Share Price: TORNTPHARM has not had significant price volatility in the past 3 months.
Volatility Over Time: TORNTPHARM's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1959 | 13,247 | Samir Mehta | www.torrentpharma.com |
Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, and marketing of generic pharmaceutical formulations in India, the United States, Brazil, Germany, and internationally. The company offers products in various therapeutic areas, including cardiovascular, central nervous system, gastro-intestinal, and women healthcare; and diabetology, pain management, gynecology, oncology, and anti-infective, as well as vitamins, minerals, and nutrients. It also provides contract manufacturing services.
Torrent Pharmaceuticals Limited Fundamentals Summary
| TORNTPHARM fundamental statistics | |
|---|---|
| Market cap | ₹911.25b |
| Earnings (TTM) | ₹14.94b |
| Revenue (TTM) | ₹104.74b |
61.0x
P/E Ratio8.7x
P/S RatioIs TORNTPHARM overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| TORNTPHARM income statement (TTM) | |
|---|---|
| Revenue | ₹104.74b |
| Cost of Revenue | ₹27.11b |
| Gross Profit | ₹77.63b |
| Other Expenses | ₹62.69b |
| Earnings | ₹14.94b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 44.15 |
| Gross Margin | 74.12% |
| Net Profit Margin | 14.27% |
| Debt/Equity Ratio | 66.9% |
How did TORNTPHARM perform over the long term?
See historical performance and comparison